Differential effects of renin-angiotensine-aldosteron system inhibition, sympathoinhibition and low sodium diet on blood pressure in women with a history of preeclampsia: A double-blind, placebo-controlled cross-over trial (the PALM study).
Adult
Angiotensin II Type 1 Receptor Blockers
/ administration & dosage
Blood Pressure
Cardiovascular Diseases
/ prevention & control
Cross-Over Studies
Dietary Approaches To Stop Hypertension
/ methods
Double-Blind Method
Female
Gestational Age
Humans
Imidazoles
/ administration & dosage
Losartan
/ administration & dosage
Postpartum Period
Pre-Eclampsia
/ diet therapy
Pregnancy
Renin-Angiotensin System
/ drug effects
Cross-over trial
Hypertension
Low sodium diet
Postpartum
Preeclampsia
Renin-angiotensin-aldosterone system inhibition
Sympathoinhibition
Journal
Pregnancy hypertension
ISSN: 2210-7797
Titre abrégé: Pregnancy Hypertens
Pays: Netherlands
ID NLM: 101552483
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
14
05
2020
accepted:
31
12
2021
pubmed:
26
1
2022
medline:
26
2
2022
entrez:
25
1
2022
Statut:
ppublish
Résumé
Current guidelines lack sufficient evidence to recommend a specific blood pressure lowering strategy to prevent cardiovascular disease after preeclampsia. We conducted a double-blind cross-over trial to identify the most potent antihypertensive strategy: renin-angiotensin-aldosterone system (RAAS) inhibition (losartan), sympathoinhibition (moxonidine), low sodium diet and placebo (n = 10). Due to low inclusion rate our study stopped prematurely. Initiatory analyses showed no significant effect of antihypertensive strategy on office blood pressure and 24-hour blood pressure. However, nocturnal dipping was significantly higher on RAAS inhibition and low sodium diet compared to placebo and sympathoinhibition. Optimal cardiovascular prevention after preeclampsia should be further explored.
Identifiants
pubmed: 35074611
pii: S2210-7789(22)00002-2
doi: 10.1016/j.preghy.2021.12.016
pii:
doi:
Substances chimiques
Angiotensin II Type 1 Receptor Blockers
0
Imidazoles
0
moxonidine
CC6X0L40GW
Losartan
JMS50MPO89
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
173-175Informations de copyright
Copyright © 2022. Published by Elsevier B.V.